Bristol-Myers Squibb keeps Strong Buy rating with 16% growth in portfolio offsetting patent losses.

Bristol-Myers Squibb maintains a Strong Buy rating due to its expanding growth portfolio, which now accounts for nearly 60% of total revenues and grew 16% year-over-year. This growth helps offset upcoming patent expirations. Key pipeline drugs include iberdomide and mezigdomide for multiple myeloma, with an FDA decision on iberdomide expected by August 2026. Additionally, Cobenfy, approved for schizophrenia, shows promise for other uses, with important Alzheimer's Disease psychosis data anticipated by the end of 2026.